Blood test may help Fine-Tune heart drug dosing
NCT ID NCT07487714
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether measuring amiodarone levels in the blood helps doctors choose the right dose for people with paroxysmal atrial fibrillation (a type of irregular heartbeat). About 80 adults will receive different daily doses (100, 200, or 400 mg) and be monitored for three months. The goal is to see if this approach reduces the return of atrial fibrillation episodes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Amiodarone
What this could lead to
If successful, this could show that adjusting amiodarone dose based on blood levels improves control of atrial fibrillation with fewer side effects.
What could go wrong
This is a small, early-phase study (80 participants) and may not prove that blood monitoring is better than standard care. Amiodarone also has known risks like thyroid and lung problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL AF are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kievskaya street 111a Cardiology research institute
Tomsk, 634012, Russia